NCE-1 Intelligence & Market Opportunity

Wayrilz

Rilzabrutinib

Immunomodulators

Oral Tablet

Wayrilz is an oral reversible BTK inhibitor indicated for adults with chronic immune thrombocytopenia (ITP). It works by modulating immune pathways to increase platelet counts and reduce the risk of bleeding, offering a convenient twice-daily oral treatment option.

Approval Date

29-Aug-25

NCE-1 Date

29-Aug-29

NCE Date

29-Aug-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

1.7124

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

102

2027

203

2028

326

2029

433

2030

582

2031

715

2032

836

Molecule profile

Details & specifications

Molecule

Rilzabrutinib

Innovator

GENZYME CORP

Dosage Form

Oral Tablet

Strength

400 mg

Therapeutic Category

Immunomodulators

Usage

To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.